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E V I D E N C E - B A S E D A N S W E R
How does colonoscopy compare 
with fecal occult blood testing 
as a screening tool for colon cancer?
■ Evidence summary
A Cochrane review conducted a meta-
analysis looking only at FOBT for colorectal
cancer screening. This review, based on 
published and unpublished data from 5 con-
trolled trials, demonstrated that 3-card home
FOBT conferred a reduction in colorectal
cancer mortality of 16% (relative risk
[RR]=0.84; 95% confidence interval [CI],
0.77–0.92) and a number needed to screen
of 1173 (95% CI, 741–2807) to prevent 
1 death from colon cancer over a 10-year
period.1 If adjusted for adherence to screen-
ing, the reduction in mortality increased to
23% (RR=0.77; 95% CI, 0.57–0.89).  
In addition, long-term follow up of
one of the RCTs in the review showed a
continued reduction in colorectal cancer
mortality of 34% (RR=0.66; 95% CI,
0.54–0.81) in subjects adhering to the
FOBT screening protocol over a 13-year
interval.2 Overall mortality did not differ
between the screened and unscreened
groups.
A systematic review performed for 
the US Preventive Services Task Force
(USPSTF) incorporated more recent data
on colorectal cancer screening including
colonoscopy.3 This review reached similar
conclusions as above. This review also
looked at office FOBT performed after dig-
ital rectal exam. It is important to note that
No studies have directly compared colonoscopy
with fecal occult blood testing (FOBT). Multiple
screening trials have demonstrated that a primary
strategy of 3-card home FOBT with follow-up
colonoscopy for positive results is associated with
a significant reduction in mortality from colorectal
cancer (strength of recommendation [SOR]: A,
based on systematic reviews of randomized and
nonrandomized controlled trials). A single negative
office-based digital FOBT does not decrease the
likelihood of advanced neoplasia (SOR: B, based
on a single prospective cohort study). 
There are no publications of screening trials
with colonoscopy, but the odds of dying from 
colorectal cancer are lower for patients undergoing
colonoscopy compared with patients not having 
a colonoscopy (SOR: B, based on extrapolation
from a case-control study). Both strategies are
cost-effective (SOR: A, based on a systematic
review of high-quality cost-effective analyses).
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C L I N I C A L C O M M E N T A R Y
For those at average risk, consider patient 
preference, likelihood of adherence to follow-up,
community resources
While a clear answer does not emerge for a 
preferred strategy for colorectal cancer screening
between FOBT and colonoscopy, colorectal cancer
causes a significant burden of suffering including
death. Clinicians must find a systematic way to
address colorectal cancer screening with their own
patient populations, and find an effective way to
determine whether their patients are at average or
increased risk for colorectal cancer.  For those at
average risk, consider patient preference, likelihood
of patient adherence to follow-up screening, and
community resources as you and your patient try
to find common ground. When discussing three-
card home FOBT with patients, make them aware
that positive test results will lead to colonoscopy.
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A 3-card home
fecal occult blood
test with follow-
up colonoscopy
for positive results
is associated with
a reduction in
mortality from
colon cancer
FAST TRACK
a single office FOBT has a lower sensitivity
than 3-card home FOBT and its effective-
ness for reducing colorectal cancer mortali-
ty was unknown at the time of the system-
atic review. A subsequent 2005 Veterans
Affairs prospective cohort study found that
the sensitivity for detecting advanced neo-
plasia was only 4.9% for digital FOBT, and
negative results did not decrease the likeli-
hood of advanced neoplasia.4
The USPSTF review did not find any
screening trials of colonoscopy but ana-
lyzed data from the National Polyp Study
and a case-control study to draw its con-
clusions.3 The review reported an odds
ratio for colorectal cancer mortality for
patients who had colonoscopy to be 0.43
(95% CI, 0.30–63).
The USPSTF review also looked at the
sensitivity and adverse effects of FOBT
compared to colonoscopy. One-time 3-
card home FOBT had a sensitivity of 30%
to 40% for detecting cancer. The sensitivi-
ty of one-time colonoscopy was difficult to
determine since it was the criterion stan-
dard examination, but it was estimated to
be greater than 90%, with a risk of perfo-
ration of 1/2000. 
The USPSTF review found both screen-
ing strategies cost-effective (<$30,000 per
additional life-year gained) compared to no
screening. FOBT had a cost per life-year
saved of $5691 to $17,805 compared with
$9038 to $22,012 for colonoscopy per-
formed every 10 years.5
Recommendations from others
The USPSTF found strong evidence to rec-
ommend screening in this age group begin-
ning at age 50 but found insufficient evi-
dence to determine a preferred strategy.
The evidence reviewed here does not apply
to patients at higher risk for colorectal can-
cer based on personal history, family histo-
ry or symptoms.  
The TABLE details the American
Cancer Society and the US Multisociety
Task Force on Colorectal Cancer’s 2003
updates recommending options for screen-
ing average-risk individuals for colorectal
cancer beginning at age 50.6,7
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T A B L E
TEST OR PROCEDURE FREQUENCY* 
3-card fecal occult blood test Annually
Flexible sigmoidoscopy Every 5 years
Double-contrast barium enema Every 5 years
Colonoscopy Every 10 years
*Beginning at age 50 for men and women.
Recommended options for screening 
average-risk individuals for colorectal cancer
